Key points are not available for this paper at this time.
The last few years of enhancing the design of hybrid mesoporous organosilica nanoparticleshas allowed their degradation under specific pathologic conditions, which finally is showing a lightin their potential use as drug delivery systems towards clinical trials. Nevertheless, the issueof controlling the degradation on-demand at cellular level still remains a major challenge, even if ithas lately been addressed through the incorporation of degradable organo-bridged alkoxysilanesinto the silica framework. On this basis, this mini review covers some of the most recent examplesof dierent degradable organosilica nanomaterials with potential application in nanomedicine,from degradable non-porous to mesoporous organosilica nanoparticles (MONs), functionalized withresponsive molecular gates, and also the very promising degradable periodic mesoporous organosilicamaterials (PMOs) only consisting of organosilica bridges.
Poscher et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: